A Revolutionary Blood Test To Detect Cancer Early, So That It Could Be Cured
What
A prescription blood test that can help detect cancers based on presence of Circulating Tumor Cells (CTCs).
For Whom
Asymptomatic adult males and females (refer to test wise age criteria - please see brochure).
How
Blood samples are evaluated for presence of circulating tumor cells (CTCs) which may be further analyzed to determine the organ or tissue of origin*.
Why
Screening is not available for all cancers. Where available, it may be an inconvenient procedure that necessitates a visit to an advanced healthcare facility. Trucheck™ requires only a blood draw to detect underlying cancer.
*Subject to bio-technical feasibility / variability and sufficiency of sample.
Revolutionary Technology
Advantages
- Non-invasive, safe, convenient, and patient-friendly.
- No need for hospitalization/visit to an advanced healthcare facility.
- No inconveniences, and no procedural risks.
- No exposure to radiation.
- Can improve the early detection of cancers for which standard screening is available.
- Can help early detection of cancers for which no screening is offered.
Effect of Our Proprietary CEM on Benign Cells, PBMCs and Cancer Cells
(CEM = CTC Enrichment Medium, PBMCs = Peripheral Blood Mononuclear Cells)
Our novel process for functional enrichment of CTCs is based on apoptosis reluctance, a hallmark of cancer cells. The process selectively eliminates all non-malignant cells (which have an intact apoptosis mechanism) while malignant cells (which evade apoptosis) survive. Circulating tumor cells and their clusters are ubiquitous in the blood of individuals with cancer and are uncommon in patients with benign conditions or otherwise healthy individuals.
Explore
Contact Us
(Messages Only)
10 Medawar Road,
The Surrey Research Park, Guildford,
Surrey, GU2 7AE, United Kingdom
Bayreuth 95447,
Germany